MedNews

  • Drug Industry News
  • FDA News & Alerts
  • Health & Medical News
You are here: Home / Health & Medical News / Diabetes / FDA Panels to Evaluate Avandia Heart Risks

FDA Panels to Evaluate Avandia Heart Risks

July 29, 2007 By MedNews Leave a Comment

Two Food and Drug Administration advisory panels will meet to discuss the results of a study done by Cleveland Clinic cardiovascular medicine chairman and a leading author, Steven Nissen, claiming that the popular diabetes drug "Avandia" may increase the risk of heart attack in patients.

Nissen’s study is based on 42 clinical trials. Results showed that people on Avandia were at 43% higher risk of having a heart attack.

Glaxo, the drug maker, reported a fall of 23% in Avandia sales after the study was published.
The advisory panel may recommend anything from no action to a black box label. However, Glaxo spokeswoman Mary Anne Rhyne maintains that these drugs are safe and the decline in sales is only in new prescriptions.

Filed Under: Diabetes Tagged With: avandia, Diabetes, fda



Leave a Reply

Your email address will not be published. Required fields are marked *

Search



Tag Cloud

alcohol allergies alzheimers antibiotics breast cancer cancer Centers for Disease Control (CDC) children cholesterol dementia depression Diabetes diet drug abuse exercise fda flu food genetics geriatrics h1n1 heart heart attack heart disease high blood pressure HIV/AIDS hormone therapy hypertension lungs menopause NIH obesity pain pediatrics pregnancy prostate cancer seniors sleep smoking statistics stroke sun teens USA women's health

Recent Comments

  • Mia Fritz on Health Benefits of Dark Chocolate
  • Shilpa on Why Too Much Iron Can Be Dangerous
  • Racheal on Teen Pregnancy May Be Reduced by Sex Education in Schools, Says Study
  • Don on Prilosec, Nexium and Prevacid Tied to Higher Risk of Pneumonia
  • Meso on Brain Changes in Elderly Can Affect Mobility and Balance
  • About Us
  • Contact

Copyright © 2025 Mednews · Log in